Micafungin Hikma

Micafungin, the active ingredient in Micafungin Hikma, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and serves as prophylaxis for Candida infections in high‑risk patients such as those undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin Hikma is an echinocandin antifungal used to manage serious Candida infections and prevent them in vulnerable patient groups. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in immunocompromised patients. - Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida species. - Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during the high‑risk post‑transplant period. - Candida peritonitis and intra‑abdominal infections: treats severe intra‑abdominal Candida infections when systemic therapy is required.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate headache. - Elevated liver enzymes: mild, reversible increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Hypersensitivity reactions: rash, pruritus, or anaphylaxis. - Severe infusion‑related reactions: hypotension or bronchospasm during administration.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Liver function: obtain baseline hepatic enzymes and monitor periodically. - Renal function: evaluate kidney status, especially in patients with concurrent nephrotoxic agents. - Concomitant antifungals: avoid overlapping therapy with other echinocandins. - Pregnancy and lactation: use only if benefit outweighs potential risk; category B. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine exposure may raise nephrotoxicity risk. - Rifampin: may reduce micafungin plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes. - Warfarin: observe INR for any unexpected shifts.